ArticleBulletin of experimental biology and medicine2025
Adaptation of Mycobacterium tuberculosis to a New Aroylhydrazone Derivative In Vitro and Possible Role of Rv3755c Gene.
Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the response of Mycobacterium tuberculosis to exposure to a new aroylhydrazone derivative using the in vitro mutagenesis followed by genomic analysis of a resistant variant. The compound N'-[(E)-(5-methoxy-1H-indol-3-yl)methylidene]furan-2-carbohydrazide showed minimal inhibitory concentration (MIC) of 0.4412 μM for the reference strain M. tuberculosis H37Rv. An H37Rv clone resistant to elevated (4 × MIC) concentration of this compound recovered on a solid medium was further analyzed by whole genome sequencing and bioinformatics tools. A non-synonymous mutation was detected in the Rv3755c gene at position 302A>G (codon 101H>R, CAC-CGC). The gene-gene interaction analysis showed that this gene belongs to a network that also includes several ABC transporter genes. The identified mutation in Rv3755c may be associated with bacterial adaptation to the selective pressure of the studied aroylhydrazone derivative and reflect a non-specific drug tolerance mechanism. The conserved M. tuberculosis protein Rv3755c, whose function is unknown, may be related to the ABC transporter efflux system.
Indexed as
Identifiers
41191237What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.